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Abstract: Recent studies highlighting mesenchymal stem cell (MSC) epigenetic memory suggest
that a different differentiation medium may be required depending on the tissue of origin.
As synovial-derived stem cells (SDSCs) attract interest we aimed to investigate the influence
of TGF-β1, BMP-2 and dexamethasone on SDSC chondrogenesis in vitro. We demonstrate that
dexamethasone-free medium led to enhanced chondrogenic differentiation at both the mRNA and
matrix level. The greatest COL2A1/COL10A1 ratio was detected in cells exposed to a combination
medium containing 10 ng/mL BMP-2 and 1 ng/mL TGF-β1 in the absence of dexamethasone, and this
was reflected in the total amount of glycosaminoglycans produced. In summary, dexamethasone-free
medium containing BMP-2 and TGF-β1 may be the most suitable when using SDSCs for cartilage
tissue regeneration.
Keywords: synovial derived stromal cell; BMP-2; TGF-β; dexamethasone; chondrogenesis
1. Introduction
Articular cartilage (AC) is the most specialized connective tissue in diarthrodial joints,
principally involved in facilitating physical movement and loading by limiting friction between
bones due to its biological properties [1].
AC mainly consists of chondrocytes organized within a dense extracellular matrix (ECM) that
is able to resist mechanical forces [2]. However, it is well known that AC has a limited capacity
of self-regeneration upon injury due to its avascular microenvironment, and the limited number of
chondrocytes that results in a low anabolic and biosynthetic ability [3]. Worldwide, traumatic injuries
and degenerative cartilage defects such as osteoarthritis are major health problems that still do not
have a definitive solution in terms of regeneration.
Current treatments possess several disadvantages associated with the limited availability of
allograft or autologous tissue, and the low and restricted chondrocyte proliferative potential, which also
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seems to decrease with age [4]. Chondrocytes also dedifferentiate into a fibroblastic phenotype during
in vitro culture [5]. To solve these problems an alternative treatment would be necessary.
Mesenchymal stromal cells (MSCs) are non-hematopoietic cells present in the niche of several adult
tissues [6] that could represent an alternative cell source [7]. They have a degree of self-renewal capacity,
in vitro chondrogenic potential [8] and relatively easy access [9]. Due to these properties, MSCs are
considered a promising cell source for tissue engineering applications in the area of cartilage repair [10].
MSCs can be isolated from several tissues including bone marrow, fat [11], dental pulp [12],
placenta [13], and also from synovial membrane [14]. Synovial-derived cells are increasingly being
considered as good candidates for the repair of cartilage due to the simplicity of isolation and natural
location within the articular joint [15] compared to cells from other sites. Earlier studies have shown
that human synovial-derived stromal cells (hSDSCs) have a strong multilineage differentiation potential
typical of MSCs, particularly toward the chondrogenic lineage [16]. Additionally, their hypertrophic
and endochondral ossification potential is lower compared to MSCs derived from bone marrow
(BMSCs) [14]. However, it is still necessary to carry out further studies before translating these cells
into the clinic.
One of the biggest challenges in the field of regenerative medicine is to find a method that can
guarantee a stable and reproducible differentiation [17]. For this reason, several research groups
have focused their attention on the study of specific growth factors, chemical compounds and
physical stimulation to induce stem-cell differentiation in a controlled manner. Of note, the protocols
used for differentiation have largely remained unchanged with little additional optimization:
adipogenic commitment requires the use of hydrocortisone, indomethacin, 3-isobutyl-1-methylxanthine,
and dexamethasone [11]; osteogenic differentiation uses L-ascorbic acid 2-phosphate, beta-glycerol
2-phosphate, and dexamethasone [12], while chondrogenesis also requires L-ascorbic acid
2-phosphate [8] and dexamethasone, with additional TGF-β1. When considering the most commonly
published differentiation protocols, the different cell sources are not often considered, and the
standard protocols are applied regardless of cell source. This overlooks the fact that different cells,
although commonly called MSCs can, and often do, respond differently to the compounds used
for differentiation as they have pre-imprinted epigenetic and transcriptomic differences that make
them differentially responsive to the environment [18,19]. This has led to an increased interest in
tissue-specific MSC differentiation media.
Secondly, the use of dexamethasone, a glucocorticosteroid drug, is common in all differentiation
protocols, independent of their commitment toward adipogenesis, osteogenesis or chondrogenesis.
Dexamethasone is a synthetic glucocorticoid used in clinical practice for the treatment of inflammation
and autoimmune conditions. It is used in the most common media for the induction of differentiation of
mesenchymal stem cells toward the mesodermal lineage. Although glucocorticoids represent one of the
most used medicaments for the treatment of many diseases, the limitation of this drug in the long term
is due to its diverse (pleiotropic) effects, including potentially harmful side effect. After their diffusion
through the cellular membrane due their lipophilic characteristic, glucocorticoids bind the respective
glucocorticoid receptor, activating a downstream up-regulation of genes involved in anti-inflammatory
responses. This occurs by directly modulating and binding DNA in the nucleus leading to gene
transcription (a process known as transactivation). Alternatively, glucocorticoids can bind and repress
the expression of proinflammatory proteins in the cytosol by preventing the translocation of NF-kB
and its heteromeric binding proteins from the cytosol into the nucleus (transrepression).
However, there are few experimental studies comparing differentiation protocols specifically
for synovium and fewer groups have investigated the role of dexamethasone during induction,
modulation and differentiation in vitro. Recently, Shintai and Hunziker have shown that the
effect of dexamethasone on chondrogenesis is dependent on cell source (tissue of origin and its
microenvironment) and on the growth factor used [20].
Based on these observations, we investigated how hSDSCs respond to the conventional TGF-β1
chondrogenesis protocol [8] and how they respond to varying concentrations of TGF-β1 and BMP-2.
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These growth factors have already been shown to influence the expression of type II collagen and
aggrecan in chondrocytes [21], the expression of chondrocyte-specific genes in bovine synovium-derived
progenitor cells [22], and in human adipose-derived stem cells [23]. Additionally, the influence of the
corticosteroid dexamethasone was investigated.
2. Materials and Methods
2.1. Isolation of Synovial-Derived Stem Cells
Chondrogenic differentiation was induced in human synovial derived stem cells isolated from
synovial membrane (n = 4: male 42 y, male 41 y, male 19 y, male 54 y; obtained with full ethical consent
approved by the Ethics Committee of the University of Freiburg as part of the “Tissue Bank for Research
in the Field of Tissue Engineering” project (GTE-2002) and the biobank “Osteo” (AN-EK-FRBRG-135/14)).
Samples were washed in 1:3 Betaisadona/phosphate-buffered saline (PBS) in Dulbecco’s modified
Eagle medium containing 4.5 g/L glucose (DMEM-HG; Gibco, Thermo Fisher, Zürich, Switzerland)
and then incubated in CollP-solution (1% collagenase) at 37 ◦C for 4 h.
After tissue digestion, the suspension cells were centrifuged at 500× g for 5 min, collected,
and seeded in flasks for expansion with DMEM-HG.
hSDSCs were seeded at a density of 3000 cells/cm2 in DMEM-HG containing 10% MSC-qualified
fetal bovine serum (FBS) (Pan Biotech, Aidenbach, Germany), 100 U/mL penicillin, 100µg/mL
streptomycin (Gibco, Thermo Fisher, Zürich, Switzerland), and 5 ng/mL recombinant human basic
fibroblast growth factor (bFGF, Fitzgerald Industries International, Acton, MA, USA). Cells were
cultured at 37 ◦C in a 5% CO2, 85% humidity atmosphere. Medium was changed every 2nd day until
70% confluence.
2.2. Induction of Chondrogenic Differentiation
Chondrogenic differentiation of hSDSCs between passage 3 and 4 was achieved using 3D pellet
culture. 2 × 105 hSDSCs per pellet were seeded in V-bottom 96-well plates (Corning, Corning, NY,
USA) and centrifuged at 400× g for 5 min.
hSDSCs were committed towards the chondrogenic phenotype by switching to a chondrogenic
medium, i.e., DMEM-HG, 1% non-essential amino acids (Gibco, Thermo Fisher, Zürich, Switzerland),
1% ITS+ (Corning), in the presence of 100 nM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA),
5 µg/mL Ascorbic acid-2 phosphate (Sigma-Aldrich, St. Louis, MO, USA) and 10 ng/mL TGF-β1
(Fitzgerald). Other groups of cells were exposed to a lower concentration TGF-β1 (1 ng/mL) alone,
or in the presence of BMP-2 at 1, 5, 10 ng/mL alone, or in double combination of 1 ng/mL TGF-β1
plus 1, 5, 10 ng/mL BMP-2; all the groups were cultured in the presence (+dexamethasone) or absence
(-dexamethasone) of 100 nM dexamethasone. Every second day the media were replaced until day 21,
when all the pellets were harvested for further analyses.
2.3. Real-Time Quantitative Polymerase Chain Reaction (PCR) Analysis
Total RNA was isolated from hSDSCs at day 0, before chondrogenic commitment, and after
21 days using TRI Reagent® Solution (Molecular Research Centre Inc., Cincinnati, OH, USA) according
to the manufacturer’s protocol. RNA quantity and quality were measured using the NanoDrop 1000
Spectrophotometer (Thermo Fisher, Zürich, Switzerland). For reverse transcription (RT) of 1 µg total
RNA, TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, USA) was used. The RT
reaction was carried out at 25 ◦C for 10 min, followed by 30 min at 42 ◦C and stopped by heating for
5 min at 85 ◦C. Relative gene expression (quantitative polymerase chain reaction (qPCR)) reactions were
set up in 10µL reaction mixtures containing TaqMan Universal Master Mix (Thermo Fisher, Zürich,
Switzerland), the appropriate set of primers and probes, DEPC-H2O and cDNA template. The reaction
program was set up as follows: 50 ◦C for 2 min, 95 ◦C for 10 min and 40 cycles of 95 ◦C for 15 s followed
by an annealing/extension step at 60 ◦C for 1 min. All the qPCR runs were performed using StepOne
Cells 2019, 8, 636 4 of 17
Studio Real-Time PCR System (Thermo Fisher, Zürich, Switzerland). Technical triplicates were used
for each target gene and for the different donors (biological replicates).
The relative expression of genes COL2A1, COL10A1, ACAN, RUNX2, SOX9, SP7 (Osterix),
MMP13, and PPARG during chondrogenic differentiation were determined using the 2(-∆∆Ct) method,
with ribosomal protein large, P0 (RPLP0) as reference gene and the day 0 sample (before chondrogenic
commitment) as calibrator.
Primer and probe sequences are shown in supplemental Table S1 (supplementary material),
while catalogue numbers of Assays-on-Demand (Applied Biosystems, Foster City, USA) are listed in
the supplemental Table S2 (supplementary material).
2.4. Histological Staining Analysis
After 21 days in different culture media, samples were harvested and fixed in 70% methanol.
One day before cutting, methanol solution was substituted with 5% sucrose and the samples were
cryosectioned at constant thickness of 10 µm.
2.5. Safranin-O/Fast Green Staining
Safranin-O staining was performed on samples at day 21. The slides were washed in dH2O
to remove the cryocompound, then stained with Weigert’s Haematoxylin solution (Sigma-Aldrich,
St. Louis, MO, USA) for 10 min and washed in tap water for 10 min. The slides were then stained for
6 min with Fast Green (Fluka #51275) and for 15 min with Safranin-O (Sigma-Aldrich, St. Louis, MO,
USA), followed by a wash with dH2O. After dehydration with increasing concentrations of ethanol,
samples were transferred to xylene and coverslipped with Eukitt mounting medium (Sigma-Aldrich,
St. Louis, MO, USA).
2.6. Immunofluorescence
After an initial wash in dH2O to remove the cryocompound, slides were transferred to methanol
for 20 min. The non-specific binding sites were blocked with 10% FBS and PBS/Tween20 for 20 min.
Primary antibody anti type II collagen (CIICI, see acknowledgement section) at a concentration of
5 µg/mL was added for 1 h at RT. Slides were washed with PBS, then the secondary antibody was added
(Alexa Fluor 488 IgG 1:800) for 1 h at 37 ◦C. After washing with PBS, the nuclei were counterstained
with 2-(4-Amidinophenyl)-1H-indole-6-carboxamidine (DAPI) 2.5 µg/mL and then coverslipped with
Eukit mounting medium (Sigma-Aldrich, St. Louis, MO, USA).
2.7. Von Kossa Staining
Von Kossa staining for calcium and mineral deposition was performed on pellets at day 21.
The slides were washed in dH2O to remove the cryocompound, then incubated for 30 min in a 5%
silver nitrate solution (Fluka #85230) in direct sunlight. After rinsing in dH2O, slides were fixed with a
5% sodium thiosulfate (Fluka #72050) solution, rinsed again in dH2O and transferred to a nuclear fast
red solution for counterstaining (Fluka #60700). After dehydration with increasing concentrations of
ethanol, samples were transferred to xylene, and then coverslipped with Eukitt mounting medium
(Sigma-Aldrich, St. Louis, MO, USA).
2.8. Macroscopic Evaluation
Morphological analysis was performed on uncut pellets to observe the possible shape and size
differences among the groups. The pellets were collected on a glass side and covered with 100 µL
of 70% methanol. A 2.5× objective on a Zeiss AxioPlan Microscope (Zeiss Microscopy GmbH, Jena,
Germany) was used to take pictures of the pellets. Radius measurements were performed using
Axiocam software (Zeiss Microscopy GmbH, Göttingen, Germany).
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2.9. Glycosaminoglycan (GAG)/DNA Measurement
Pellet samples after 21 days were digested with 0.5 mg/mL proteinase-K (Sigma-Aldrich, St. Louis,
MO, USA) at 56 ◦C overnight, followed by deactivation at 95 ◦C for 10 min. DNA content was measured
with Hoechst 33,258 (Sigma-Aldrich, St. Louis, MO, USA) using a microplate reader (Victor3 Micro
Plate Reader, Perkin Elmer, Waltham, MA, USA) with excitation at 360 nm and emission at 465 nm
according to published methodology [24]. The amount of glycosaminoglycan (GAG) in the scaffolds
and medium was determined by the dimethylmethylene blue dye method [25].
2.10. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7.03 software (GraphPad Software,
San Diego CA, USA). Non-parametric two-way analysis of variance (ANOVA) in conjunction with
Tukey’s multiple comparison test was applied. p < 0.05 was considered as statistically significant.
A two-way ANOVA was used to evaluate distribution and homogeneity variance in the groups;
the Tukey’s multiple comparison was used to evaluate the means of the different groups.
3. Results
3.1. Gene Expression Analysis
3.1.1. TGF-β1 and BMP-2 Alone and in Combination Induces Chondrogenic Differentiation
To detect and clarify the role of two growth factors (TGF-β1 and BMP-2) during chondrogenic
commitment of synovial-derived stem cells, both alone and in combination, the analysis of gene
expression in pellet cultures was performed with qPCR.
The mRNA level of common markers associated with chondrogenic commitment during
differentiation were significantly upregulated in all cells cultured with growth factors, independent of
dexamethasone presence. Aggrecan (ACAN) expression was strongly modulated by TGF-β1 and
BMP-2, with a p≤ 0.001 compared to the negative control pellets that were not exposed to growth factors.
The increase in ACAN expression was greater when the cells were not exposed to dexamethasone
(Figure 1A). The combination of TGF-β1 (1 ng/mL) and BMP-2 (1 ng/mL, 5 ng/mL and 10 ng/mL)
further increased ACAN mRNA expression.
Following the same pattern, collagen II (COL2A1) was upregulated in cells exposed to TGF-β1
alone, although the presence or absence of dexamethasone did not affect COL2A1 expression when
only TGF-β1 was used. Higher dose BMP-2, with or without TGF-β1, led to an increased COL2A1
expression in the absence of dexamethasone when compared to dexamethasone-containing medium
(Figure 1B).
3.1.2. The SOX9/RUNX2 Ratio as a Marker of Chondrogenic Potential of Human Synovial-Derived
Stromal Cells (hSDSCs) In Vitro
To assess the chondrogenic potential of hSDSCs upon TGF-β1 and BMP-2 stimulation,
the expression of two transcription factors involved in osteochondral fate was studied. Previous studies
clearly showed that the RUNX2/SOX9 ratio is a promising and early predictor marker for in vitro
osteogenic potential of BMSCs [26,27]. RUNX2 was largely unaffected by the different treatments
(Figure 1D); however, while a low dose of TGF-β1 alone had little effect on SOX9 expression,
10 ng/mL TGF-β1 led to its increase (Figure 1C). This suggests that during osteochondral fate a pivotal
transcription factor modulated by TGF-β1 or BMP-2 is SOX9, which seems to be strongly affected
using dexamethasone. In the absence of the glucocorticoid, the addition of BMP-2 led to a significantly
increased SOX9 expression. In the higher dose combination groups, the increases observed were less
dependent on the presence of dexamethasone. RUNX2 expression, however, was not controlled by
TGF-β1 or BMP-2, suggesting a possible role of glucocorticoids action on the SOX9/RUNX2 balance by
way of changes in SOX9 expression (Figure 1E).
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β1. Experimental groups contained low TGF-β1 concentrations (1 ng/mL TGF-β1), various 
concentrations of BMP-2 alone (1 ng/mL BMP-2, 5 ng/mL BMP-2, 10 ng/mL BMP-2), or BMP-2 in 
combination with 1 ng/mL TGF-β1 (1 ng/mL TGF-β1+1 ng/mL BMP-2, 1 ng/mL TGF-β1+5 ng/mL 
BMP-2 and 1 ng/mL TGF-β1+10 ng/mL BMP-2). The amounts of ACAN (A), COL2A1 (B), SOX9 (C), 
RUNX2 (D) mRNA were normalized to 60S acidic ribosomal protein P0 (RPLP0) and SOX9/RUNX2 
Figure 1. Effect of TGF-β1 and BMP-2 on the expression of genes orchestrating human synovial-derived
stromal cell (hSDSC) chondrogenic commitment. Cells were induced to chondrogenic differentiation for
21 days in the pr s nce (positive co trol) or absence (negative) of 10 ng/mL TGF-β1. Experimental groups
contained low TGF-β1 concentrations (1 ng/mL TGF-β1), various concentrations of BMP-2 alone
(1 ng/mL BMP-2, 5 ng/mL BMP-2, 10 ng/mL BMP-2), or BMP-2 in combination with 1 ng/mL TGF-β1
(1 ng/mL TGF-β1+1 ng/mL BMP 2, n L TGF-β1+5 ng/mL BMP-2 and 1 ng/mL TGF-β1+10 ng/mL
BMP-2). The amounts of ACAN (A), COL2A1 (B), SOX9 (C), RUNX2 (D) mRNA were normalized to
60S acidic ribosomal protein P0 (RPLP0) and SOX9/RUNX2 ratio (E) was calculated as the ratio between
the fold change of each gene. The levels of gene expression of cells exposed to different media in the
presence or absence of 100 nM dexamethasone were plotted as a fold change relative to the expression
of the corresponding gene in undifferentiated cells (hSDSC day 0) defined as 1 (mean ± standard
deviation (SD); n = 4). All data from 10 ng/mL TGF-β1 (positive control), low TGF-β1 concentration
(1 ng/mL TGF-β1), and 1 ng/mL TGF-β1 combination with BMP-2 (1 ng/mL TGF-β1 + 1 ng/mL BMP-2,
1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1 + 10 ng/mL BMP-2) were significantly different
from negative control. Grey bars represent scatterplot of different measurements in hSDSC exposed
to dexamethasone; red bars represent scatterplot of different measurements in hSDSC not exposed
to dexamethasone. Data are expressed as mean ± SD, significant differences from dexamethasone
treatment in the same group are marked by red asterisks; significant differences among group are
marked by black asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).
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In the higher dose combination groups, the SOX9/RUNX2 ratio was further enhanced when
dexamethasone was not supplemented into the culture medium (Figure 1E).
3.1.3. TGF-β1 Influences COL10A1 Expression
Figure 1B shows COL2A1 upregulation using TGF-β1 alone, but contrary to ACAN the presence or
absence of dexamethasone did not affect its expression. With a similar trend, TGF-β1 alone increased
COL10A1 expression, however it was interesting to observe that COL10A1 was further increased in
dexamethasone-containing medium, while BMP-2 alone had little effect both in the presence or absence
of dexamethasone (Figure 2A). The role of the glucocorticoid was most striking in the combination
groups. When 1 ng/mL TGF-β1 was combined with either 1 or 5 ng/mL BMP-2, no increase in COL10A1
was observed when dexamethasone was absent, but the levels of COL10A1 increased in its presence.
Even in the high-dose BMP-2 combination group, the presence of the glucocorticoid increased COL10A1
expression over dexamethasone-free medium, suggesting an important role of dexamethasone in the
determination of hypertrophy when TGF-β is present.
When comparing the COL2A1/COL10A1 ratio, in order to establish the stability of chondrogenic
differentiation, an increase was observed with 10 ng/mL TGF-β1 alone in either the presence or absence
of the glucocorticoid (Figure 2B). With 1 ng/mL of TGF-β1 alone, the ratio was higher in the absence
of dexamethasone. The absence of dexamethasone also leads to an improved COL2A1/COL10A1
ratio, meaning that cells were expressing higher levels of COL2A1 compared to COL10A1 in the
higher BMP-2 concentration groups. With the same trend, in the combination groups there was a
dose-dependent increase in COL2A1/COL10A1 ratio with increasing BMP-2 concentration, that was
significantly enhanced by the absence of dexamethasone.
3.1.4. Exposure to Corticosteroid Regulates MMP13 Expression, while COL1A1 Is only Influenced
by BMP-2
Another important marker associated with chondrogenic differentiation is type I collagen, a major
fibrillar component of undifferentiated mesenchymal progenitor cells and typical for fibrocartilage.
Here we assessed the quality of chondrogenic differentiation and whether it was directed more into
hyaline cartilage or to fibrocartilage using the COL1A1 and COL2A1/COL1A1 ratio as markers. In the
groups containing TGF-β1, COL1A1 expression increased over the negative control, with or without
exposure to dexamethasone (Figure 2C). Interestingly, with the use of only BMP-2, COL1A1 expression
increased but only in the absence of dexamethasone. Overall, the COL2A1/COL1A1 ratio was largely
unaffected by dexamethasone and it reached the highest value in the group exposed to 1 ng/mL TGF-β1
+ 10 ng/mL BMP-2 (Figure 2D).
Chondrogenic differentiation may also be monitored by assessing the expression of MMP13
(Matrix Metallopeptidase 13), a gene that encodes for a protein that plays a role in the degradation
of extracellular matrix proteins including fibrillar collagen, fibronectin and aggrecan. In this study
dexamethasone inhibited the expression of MMP13 under all conditions (Figure 2E). The differences in
MMP13 expression between dexamethasone-containing and dexamethasone-free media were most
pronounced in groups containing TGF-β1. This suggests that during differentiation, in parallel with
the expression of genes associated with a good quality of chondrogenesis, such as COL2A1 and
ACAN (Figure 1A–B), TGF-β1 induces the expression of MMP13 and this can be attenuated by the use
of dexamethasone.
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Figure 2. Dexamethasone modulates COL10A1 expression, a hypertrophy marker, in hSDSCs exposed to
TGF-β1 and BMP-2. Cells were cultured for 21 days in the presence of 10 ng/mL TGF-β1 (positive control)
or in its absence (negative), low TGF-β1 concentration (1 ng/mL TGF-β1), different concentrations of
BMP-2 alone (1 ng/mL BMP-2, 5 ng/mL BMP-2, 10 ng/mL BMP-2) r BMP-2 in combination with TGF-β1
(1 ng/mL TGF-β1 + 1 ng/mL BMP-2, 1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1 + 10 ng/mL
BMP-2). The amounts of COL10A1 (A), COL1A1 (C) and MMP13 (E) mRNAs were normalized to
RPLP0. The ratio between COL2A1 and COL10A1 (B) and COL2A1 and COL1A1 (D) was calculated
as the ratio between the fold change of each gene. The levels of gene expression of cells exposed to
different media in the presence or absence of 100 nM dexamethasone were plotted as a fold change
relative to the expression of the corresponding gene in undifferentiated cells (hSDSC day 0) defined
as 1 (mean ± SD; n = 4). Grey bars represent scatterplot of different measurement in hSDSC exposed
to dexamethasone, red bars represent scatterplot of different measurement in hSDSC not exposed to
dexamethasone. Data are expressed as mean ± SD, significant difference from dexamethasone treatment
in the same group is marked by red asterisks; significant difference among group is marked by black
asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).
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3.1.5. Dexamethasone Enhances Osteogenic Gene Expression when Combined with TGF-β1
During mesodermal differentiation, cell fate could be easily affected by activation of unwanted
pathways that decrease the yield and quality of differentiation. Since the likelihood of osteochondral
differentiation at the expense of a stable chondrogenesis is high, we tested the expression of the
osteogenic marker Osterix (SP7), a gene that encodes a member of the Sp subfamily of Sp/XKLF
transcription factors. Sp family proteins are sequence-specific DNA-binding proteins essential
for osteoblast differentiation [28]. The expression of SP7 increased when 10 ng/mL TGF-β1 and
dexamethasone were combined, while little change was seen in the absence of dexamethasone or at the
lower TGF-β1 concentration (Figure 3A). BMP-2 alone had little influence of the expression of SP7.
However, the combination of TGF-β1 and BMP-2 induced a dose-dependent increase in SP7 expression
that was lower in the absence of dexamethasone (Figure 3A). Therefore, dexamethasone increases the
expression of SP7 in the presence of TGF-β1, inducing an osteogenic or hypertrophic-like phenotype
compared to cells in dexamethasone-free media.Cells 2019, 8, x FOR PEER REVIEW 10 of 19 
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Figure 3. Dexamethasone modulates SP7 (Osterix) and PPARG genes expression in hSDSCs exposed to
TGF-β1 and BMP-2. Cells were c ltured for 21 days in the presence of 10 ng/mL TGF-β1 (positive control)
or in its absence (negativ ), low TGF-β1 concentration (1 ng/mL TGF-β1), various concentrati ns of
BMP-2 al ne (1 ng/mL BMP-2, 5 ng/mL BMP-2, 10 ng/mL BMP-2) or BMP-2 in combination with
TGF-β1 (1 ng/mL TGF-β1 + 1 g/mL BMP-2, 1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1
+ 10 ng/mL BMP-2). The amounts of SP7 (A) and PPARG (B) mRNA were normalized to RPLP0.
The levels of gene expression of cells exposed to different media in the presence or abs nce f 100 nM
dexamethasone w re plotted as a fold change relative to the expression of the correspo ding gene in
undifferentiated cells (hSDSC day 0) defined 1 (mean ± SD; n = 4). Grey bars represent scatterplot
of different measureme t in hSDSC exposed to dexamethaso , red bars represent scatterplot of
different measurement in hSDSC not exposed to dexamethasone. Data are expressed as mean ± SD;
significant difference from dexamethasone treatment in the same group is marked by red asterisks;
significant difference among groups is marked by black asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001).
3.1.6. PPARG Is Regulated by TGF-β1
With the sam principle, we further investigated if our differentiation protocol, and as well the use
of dexamethasone, was influencing adipogenic differentiation of SDSCs. PPARG is a gene that encodes
a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors
and it is one of the principal regulators of adipocyte differentiation. The use of BMP-2 alone had no
effect on PPARG expression (Figure 3B); on the other hand, TGF-β1 in the absence of dexamethasone
strongly decreased PPARG expression, alone or in combination with BMP-2. This effect was more
pronounced in the combination groups.
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3.2. Biochemical Analyses
TGF-β1 Influences Pellet GAG Content
Dexamethasone treatment generally led to an increased DNA content (Figure 4A) and this effect
was more pronounced at the lowest TGF-β1 concentration (p ≤ 0.05) and as BMP-2 concentration
increased. In the combination groups, there was a dose-dependent increase in DNA content (Figure 4A)
and this was even more pronounced in the presence of dexamethasone. By day 21, combination group
pellets cultured in dexamethasone-free media showed the highest GAG content (Figure 4B). However,
GAG/DNA in the pellet was comparable between groups, with the absence of dexamethasone showing
higher values (Figure 4C). The combination groups also demonstrated a higher GAG content in the
absence of dexamethasone (Figure 4D).Cells 2019, 8, x FOR PEER REVIEW 11 of 19 
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larger pellets, with only the 10 ng/mL TGF-β1 group being unaffected by glucocorticoid addition. 
Although smaller, pellets grown in the absence of dexamethasone appeared denser as determined by 
a decrease in light transmission (Figure 5). 
Figure 4. The effect of dexamethasone on glycosaminoglycan and DNA content in the pellets. Cells were
cultured for 21 days in the presence of 10 n /mL TGF-β1 (positive control) r in i s absenc (negative),
low TGF-β1 concentration (1 ng/mL TGF-β1), various concentration of BMP-2 alone (1 ng/mL BMP-2,
5 n /mL BMP-2, 10 ng/mL BMP-2) or BMP-2 in combination with TGF-β1 (1 ng/mL TGF-β1 + 1 ng/mL
BMP-2, 1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1 + 10 ng/mL BMP-2) (A). The amount
of glycosaminoglycans in the pellets were normalized to the DNA content (B) (mean ± SD; n = 4).
Total GAG is shown as GAG released in the medium (white bars) plus GAG retain d inside the pellets
pink bars) (C). Grey bars represent different measur m nt in SDSC exposed o dexamethasone,
d bars differ nt measurement in hSDSC in dexamethasone-free media. DNA cont nt for pellets are
shown in panel (D). Data a exp essed as mean ± SD, significant difference from dexamethasone
treatment in the sam group is marked by red asterisks; significant difference a ong groups is marked
by black asterisks (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).
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3.3. Histological Analysis
3.3.1. BMP-2 Modulates Pellet Size Differently in the Presence of Dexamethasone
In general, the addition of dexamethasone in the differentiation media led to the formation of
larger pellets, with only the 10 ng/mL TGF-β1 group being unaffected by glucocorticoid addition.
Although smaller, pellets grown in the absence of dexamethasone appeared denser as determined by a
decrease in light transmission (Figure 5).C lls 2019, 8, x FOR PEER REVIEW 12 of 19 
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Figure 5. Macroscopic evaluation of pellet size from hSDSCs exposed to TGF-β1 and BMP-2 in
the presence or absence of dexamethasone. hSDSCs in 3D culture were cultures for 21 days in the
presence of 10 ng/mL TGF-β1 (positive control) or in its absence (negative), low TGF-β1 concentration
(1 ng/mL TGF-β1), various concentrations of BMP-2 alone (5 ng/mL BMP-2, 10/mL ng BMP-2)
or BMP-2 in combination with 1 ng TGF-β1 (1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL
TGF-β1 + 10 ng/mL BMP-2). The figures are representative of four separate experiments in four
different donors (A). Radius sizes are expressed in µm (B–C). Radius pellet measured with Axio Plan
Microscope objective 2.5×.
3.3.2. Safranin-O Staining Confirms Dexamethasone Influence during hSDSC Chondrogenic
Differentiation
To validate gene expression data at the matrix and protein level, pellets were stained on day 21
with Safranin-O/Fast Green. Pellets grown in conventional 10 ng/mL TGF-β1 media had increased
GAG staining, with a more intense stain observed in the dexamethasone-free media. BMP-2 alone
did not show any positive staining for GAG, either in the presence or absence of dexamethasone.
In combination with TGF-β1, increasing BMP-2 concentration led to increased staining for GAG,
an effect that was even more pronounced in the absence of dexamethasone (Figure 6).
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Figure 6. Safranin-O/Fast Green staining of hSDSC pellets exposed to TGF-β1 and BMP-2 in the
presence or absence of dexamethasone. hSDSCs in 3D culture were cultured for 21 days in the
presence of 10 ng/mL TGF-β1 (positive control) or in its absence (negative), low TGF-β1 concentration
(1 ng/mL TGF-β1), various concentration of BMP-2 alone (1 ng/mL BMP-2, 5 ng/mL BMP-2, 10 ng/mL
BMP-2) or BMP-2 in combination with 1 ng/mL TGF-β1 (1 ng/mL TGF-β1 + 1 ng/mL BMP-2, 1 ng/mL
TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1 + 10 ng/mL BMP-2). The intensity of Safranin-O (Red)
staining is directly proportional to the proteoglycan content inside the pellet, while green structures
represent the counterstaining with Fast Green solution. The figures are representative of four separate
experiments in four different donors. Black scale bar for 10× objective = 200µm, yellow scale bars for
40× objective = 1000 µm.
3.3.3. Anti-Collagen II Immunohistochemical Staining Confirms Dexamethasone Influence during
hSDSC Chondrogenic Differentiation
To detect and quantify the content of the type II collagen matrix deposition in hSDSC pellets,
immunofluorescence staining for type II collagen was performed. The use of 10 ng/mL TGF-β1
without dexamethasone showed the strongest positivity for type II collagen (Figure 7A). Interestingly,
compared to BMP-2 alone or to 1 ng/mL TGF-β1, the combination groups also showed a positive
reaction, albeit not as strong as 10 ng/mL TGF-β1. Also, as expected, the pellets that were exposed to
dexamethasone showed a weaker positive reaction with dexamethasone-free media, the same tendency
that could be observed in the Safranin-O/Fast Green staining (Figure 7B).
3.3.4. Von Kossa Staining Analysis for Calcium and Mineral Deposition
To detect and quantify the mineral and calcification deposition of the hSDSC pellets, von Kossa
staining was performed. No mineralization or calcification could be detected in any group,
indicating that the pellets were not undergoing calcification (data not shown).
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21 days in the presence of 10 ng/mL TGF-β1 (positive control) or in its absence (negative), low TGF-β1
concentration (1 ng/mL TGF-β1), various concentration of BMP-2 alone (1 ng/mL BMP-2, 5 ng/mL
BMP-2, 10 ng/mL BMP-2) or BMP-2 in combination with 1 ng/ml TGF-β1 (1 ng/mL TGF-β1 + 1 ng/mL
BMP-2, 1 ng/mL TGF-β1 + 5 ng/mL BMP-2 and 1 ng/mL TGF-β1 + 10 ng/mL BMP-2). The intensity of
type II collagen antigen reaction was comparable to the Safranin-O/Fast Green staining. Green color
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representative of four separate experiments in four different donors. Yellow scale bar is 250 µm.
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4. Discussion
MSCs offer hope for tissue regeneration in difficult-to-replace tissues, such as cartilage.
Recent studies have highlighted the role of epigenetic memory on MSC differentiation [29] and
this suggests that cells from different sources may require differentiation media optimized for each cell
source. The classical chondrogenic differentiation medium was optimized for bone marrow derived
MSCs [8]. However, it has already been demonstrated that chondrogenesis of adipose-derived MSCs
can be improved with the addition of BMP-6 [30]. Previous studies have also shown that different cells
respond differentially to stimulation with the same growth factor [21]. Based on these observations,
we evaluated how synovium-derived cells respond to TGF-β1, and BMP-2, and their combination,
both in the presence or absence of dexamethasone.
Dexamethasone is a common factor present in all differentiation media, independent of induction
toward chondrogenesis, adipogenesis or osteogenesis. This suggests that the use of dexamethasone is
not a crucial committer towards a specific differentiation lineage, but a modulator during stem cell fate.
During chondrogenic differentiation, ACAN, COL2A1 and SOX9 were upregulated in the
presence of the conventional concentration of TGF-β1. The combination of TGF-β1 and BMP-2
also led to chondrogenic differentiation. However, removal of 100 nM/mL dexamethasone improves
chondrogenesis in the positive control (10 ng/mL TGF-β1) and in the TGF-β1/BMP-2 combination
groups. Those data were confirmed via histological evaluation, which showed a higher positivity
for GAG and type II collagen staining in cells not exposed to dexamethasone. These results are in
line with our former findings where we could show a chondrogenic differentiation of SDSCs in a
trans-well coculture of SDSC and chondrocytes induced by paracrine factors, such as TGF-β levels in
the supernatants, without dexamethasone. The trans-well coculture of human synovial mesenchymal
stem cells with chondrocytes leads to self-organization, chondrogenic differentiation, and secretion of
TGF-β [31]. Previous studies have also shown the detrimental effect of 100 nM/mL dexamethasone on
SDSC chondrogenic differentiation [32]. The same paper showed that 10 nM/mL dexamethasone also
inhibited chondrogenesis when BMP-2 alone was used, compared to TGF-β alone [32]. The discrepancy
between absolute levels of ACAN expression and the resulting GAG synthesis has been highlighted in
previous studies yet the reason for the discrepancy is so far unknown [33,34].
Additionally, dexamethasone led to an increased expression of the hypertrophic marker COL10A1.
Absence of the glucocorticoid led to a greater increase in COL2A1 expression, therefore leading
to a higher COL2A1/COL10A1 ratio, suggesting a less hypertrophic phenotype. As hypertrophy
(high collagen 10 and low collagen 2) is associated with a temporary cartilage template that will
remodel into bone, a higher COL2A1/COL10A1 ratio is considered beneficial for resting cartilage.
MMP13 is a member of the matrix metalloproteinase family, that plays a role in the degradation
of extracellular matrix proteins including collagen [35] and indicates a worse clinical outcome [36].
Dexamethasone clearly downregulated MMP13 expression, most notably when TGF-β1 was present.
MMP13 is a hypertrophic marker [37] and is believed to be involved in the transition phase of cells
toward an osteochondral fate [38] and has also been linked to osteoarthritis [39].
It is interesting to note that the GAG production in cells that were not treated with dexamethasone
was significantly higher than in those treated with dexamethasone. Both GAG retention within the
pellet and GAG release into the medium was higher when dexamethasone was absent, however in the
combination group of BMP-2 and TGF-β1 there was less retention of GAG.
The influence of dexamethasone, BMP-2, TGF-β1, and their combination on other differentiation
pathways was also investigated [40]. Osterix (encoded by SP7 gene) is a transcription factor implicated in
osteogenic differentiation, together with RUNX2, and it is upregulated by TGF-β1 also in BMSCs [41,42].
These factors are also implicated in hypertrophic differentiation during chondrogenesis, so further
work would need to be performed to establish which pathway is being preferred. Dexamethasone
had a limited effect on SP7 expression, which was more regulated by growth factor combinations [43].
The influence of TGF-β1 and BMP-2 on adipogenic commitment was investigated using PPARG as a
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marker [44]. PPARG was largely unaffected by the conditions applied. However, there was a tendency
towards a lower expression when dexamethasone was absent and TGF-β1 was present.
5. Conclusions
In conclusion, chondrogenic differentiation in the absence of dexamethasone leads to a more
stable chondrogenic phenotype when hSDSCs are used as cell source. Therefore, based on the observed
results, we suggest the use of a low TGF-β1 concentration in combination with BMP-2 to induce
chondrogenic differentiation without the use of dexamethasone. As it has been demonstrated that
kinematic load increases the production and activation of endogenous TGF-β1 [45,46], future clinical
strategies might employ the implantation of SDSCs with BMP-2 (which is clinically approved) with the
TGF-β1 component being generated endogenously by way of an optimised rehabilitation protocol.
This could pave the way for the study of different methods for the differentiation of synovial cells,
a relevant cell source that could be used in the field of regenerative medicine for patients with severe
cartilaginous problems.
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